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Abstract
Background: Despite advances in treatment, multiple myeloma (MM) remains incurable and results in significant
morbidity and mortality. Further research investigating where MM patients die and characterization of end-of-life
hospitalizations is needed.
Methods: We utilized the National Inpatient Sample (NIS) to explore the hospitalization burden of MM patients at
the end of their lives.
Results: The percent of patients dying in the hospital as a percent of overall MM deaths ranged from 54% in 2002
to 41.4% in 2017 (p < 0.01). Blood transfusions were received in 32.7% of these hospitalizations and infections were
present in 47.8% of patients. Palliative care and/or hospice consultations ranged from 5.3% in 2002 to 31.4% in 2017
(p < 0.01).
Conclusion: Our study demonstrates that patients with MM dying in the hospital have a significant requirement for
blood transfusions and have a high infection burden. We also show that palliative care and hospice involvement at
the end of life has increased over time but remains low, and that ultimately, inpatient mortality has decreased over
time, but MM patients die in the hospital at a higher rate than the general population.
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Introduction
Due to the routine incorporation of highly effective
agents such as proteasome inhibitors, immunomodula-
tory drugs and anti CD38 targeting drugs, there has been
a dramatic improvement in survival for patients with
myeloma [1–3].. However, even with these advances in
management, MM is projected to cause 13,000 deaths in
the United States annually [4].
Despite these significant number of deaths, there is
limited data on the manner and environment in which
MM patients die. Previous work focusing mostly on
early mortality has demonstrated that renal failure and
infection are leading causes of death [5]. However, fur-
ther research on mortality is needed including examin-
ing where MM patients primarily die, whether it be in
the hospital or at home, and use of supportive care ser-
vices including transfusions, antibiotics, and specialty
services such as palliative care or hospice.
To better understand these questions and provide bet-
ter context to the mortality of MM patients, we utilized
the National Inpatient Sample (NIS) to explore the
hospitalization burden of MM patients at the end of
their lives.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: gmohy-ud-din@kumc.edu
This work was previously presented as an oral presentation at the American
Society of Hematology Annual Meeting 2020.
1Department of Hematological Malignancies and Cellular Therapeutics,
Kansas University Medical Center, Kansas City, USA
Full list of author information is available at the end of the article




The NIS is a database compiled by the Agency for
Healthcare Research and Quality (AHRQ) annually since
1988. The number of States participating in the NIS has
grown from 8 in the first year to 47, plus the District of
Columbia, currently. Approximately 20% of national ad-
missions are tracked and weighted estimates are pro-
vided regarding the total number of hospitalizations [6].
Unweighted, it contains data from more than 7 million
hospital stays each year including patient demographics,
primary and secondary diagnoses, procedures, length of
stay, and disposition. Each observation within the data-
base comprises a unique hospitalization. However, the
NIS does not identify individual patients and recurrent
hospitalizations are recorded as distinct observations [7].
It also does not capture outpatient encounters,
observation-only stays, or stays in long-term acute care
hospitals or rehabilitation centers.
Study population
Using the NIS, all patients discharged from a hospital
setting with an International Classification Code (ICD)
for multiple myeloma from the years 2002 to 2017 were
collected. Patients who were noted to die in hospital
were then sub-selected (Fig. 1). ICD 9 and ICD 10 codes
were then used to gain insight into trends in transfu-
sions, infectious complications, and costs for admission.
For demographics, a Chi-square test was utilized to
compare variables of gender, comorbidity and race be-
tween years 2006 and 2017, whereas a pooled t-test was
used for age. All ICD codes utilized are shown in the
supplement. Overall annual number of deaths for MM
in the United States was obtained from publicly available
reports from the Centers for Disease Control (CDC) and
Prevention and the National Cancer Institute (NCI).
Outcomes
The primary endpoint of our study was to determine the
percentage of patients with multiple myeloma dying in
the hospital and investigate these trends from 2002 to
2017. Secondary endpoints included palliative care/hos-
pice consultation during this time period and prevalence
of infection, need for transfusions and charges related to
hospitalization. Infection frequency was identified using
the Clinical Classification Software that allows for clus-
tering patient diagnoses and procedures into clinically
meaningful categories. Demographic information on age,
sex, race and comorbidity were collected and we also
ascertained whether or not the hospitalization in ques-
tion was associated with treatment of MM by using ICD
codes for chemotherapy administration.
Results
During the time period from 2002 to 2017, the CDC re-
ported a total of 180,924 MM deaths ranging from 10,
913 in 2002 to 12,322 in 2017. The NIS identified an es-
timated national total of 1,446,809 hospitalizations for
Fig. 1 Flowchart Outlining Selection of Patients
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MM during this time period. Amongst these, an estimate
of 85,816 hospitalizations resulted in deaths. Thus, 6.3%
of all hospitalizations for MM patients resulted in death.
During our study time period, 47.4% of all deaths related
to MM in the United States occurred in the hospital.
The percent of patients with MM dying in the hospital
as a percent of overall myeloma-related deaths ranged
from 54% in 2002 to 41.4% in 2017, p < 0.01.
Proportion of hospitalizations and mortality related to
chemotherapy
There were a total of 54,357 admissions for chemother-
apy from 2002 to 2017, out of which 1.01% resulted in
mortality, for a total of 547 deaths. Thus, only 547 of the
85,816 of the overall deaths were in hospitalizations in
which chemotherapy was administered, representing
only 0.64% of all the deaths during this time period.
Demographic trends
Demographic trends of MM patients who died during
hospitalizations from 2006 to 2017 are outlined in
Table 1. Data prior to 2006 for comparison as the infor-
mation in the dataset for these years could not accur-
ately code for kidney function. The average age of death
was seen to be similar at 71.49 years in 2006 vs. 72.37
years in 2017 (p < 0.077). A slightly higher proportion of
female deaths compared to males at 57.9% vs. 42.1% was
seen in 2017 vs. 2006 when the proportion was 53.5% vs.
46.5% (p < 0.04). Upon examining the ethnic background
of these patients, black patients had an increased pro-
portion in the 2017 population at 22.04% of all hospitali-
zations leading to death vs. 14.30% in 2006 (p < 0.005),
however, a large number of patients had missing data in
2002 (Table 1).
Blood transfusion usage
We assessed blood transfusion dependency in the
hospitalization leading to death. Blood transfusions were
received (32.7%) in 39,393 of the 85,816 admissions lead-
ing to death.
Infection burden
A total of 41,063 infections were identified amongst the
85,816 hospitalizations leading to death (47.8%).
Palliative care/hospice involvement
We analyzed palliative care/hospice involvement dur-
ing the hospitalization leading to death from 2002 to
2017. Palliative care/hospice was consulted in 67 of
the 1260 hospitalizations in 2002 (5.3%), and in-
creased in 2017, whereas a palliative care/hospice
consultation was seen in 321 out of the 1021 hospi-
talizations in (31.44%) (p < 0.01). Figure 2 highlights
the trend of these consultations.
Cost
We evaluated the charge of each MM hospitalization
leading to death. Median cost of the hospitalization
leading to death after adjustment for inflation in-
creased over time from $62, 202 in 2002 to $150,451
in 2017, p < 0.001.
Discussion
Our study is the first to use a nationwide database to
compare with publicly available mortality data to provide
an estimate of the overall percentage of deaths from
MM occurring in the hospital. Our study shows that
despite advances in MM therapy and supportive care,
greater than 40% of patients with MM continue to die in
the hospital as of 2017, although there has been a re-
assuring decrease since 2002. This trend mirrors data for
overall deaths in the hospital in the US, which has
shown that 48.0% of deaths from all causes occurred in
hospital in 2000 but decreased to 35.1% in 2014 [8]. Our
analysis thus demonstrates that patients with MM
continue to die in the hospital at greater rates than the
general population, findings that have also been demon-
strated for other hematological malignancies such as
leukemia [9].
As only a small proportion of hospitalizations were re-
lated to chemotherapy, which are often planned admis-
sions with a therapeutic intent, our data reflects that the
Table 1 Demographics of Studied Population
Demographics table
Year 2006 2017 P-value
Demographic % # % #
Age 71.49 (mean) 72.37 (mean) 0.077
Gender
Male 46.5% 527 42.1% 430 0.04
Female 53.5% 606 57.9% 591
CKD stage V 1.20% 14 0.90% 9 0.425
End Stage Renal Disease 14.80% 168 12.70% 130 0.160
Hypertension 44% 503 12% 127 < 0.001
Congestive Heart Failure 33.00% 374 33% 379 0.924
Race
White 49.96% 566 57.00% 582 0.005
Black 14.30% 162 22.04% 225
Hispanic 5.65% 64 9.50% 97
Asian or Pacific Islander 1.85% 21 2.74% 28
Native american 0.71% 8 0.49% 5
Other 1.85% 21 4.41% 45
Missing 25.68% 291 3.82% 39
Total 1133 1021
Abbasi et al. BMC Cancer          (2021) 21:339 Page 3 of 6
vast majority of hospitalizations resulting in death for
MM patients reflect unplanned admissions. This paper
did not specifically account for deaths in the
hospitalization for a stem cell transplantation amongst
overall inpatient deaths. However, we previously have in-
terrogated the National Inpatient Sample to evaluate for
autologous transplantation related hospitalizations, and
the total weighted number of inpatient admissions for
stem cell transplantation among MM patients was 47,
253 from 2002 to 2014, with an inpatient mortality ran-
ging from 1.8% in 2002 to 0.7% in 2014. Thus only a
small minority of deaths in the hospital from our dataset
would have been related to a hospitalization for trans-
plantation [10].
We also observed an increase in the proportion of Af-
rican Americans dying in the hospital over time, which
is consistent with other studies of African American pa-
tients with malignancy that have higher shown likeli-
hood of dying in acute care setting [11–13]. We would
however draw caution in interpreting this finding as in-
ferences on race from the National Inpatient Sample is
problematic due to a high proportion of patients with
“missing” race in earlier years, and that race is variably
and inconsistently reported between states.
Our analysis demonstrates significant transfusion re-
quirements and infections seen at the end of life with
MM patients. We observed that infections were identi-
fied in a notable 45% of MM hospitalizations leading to
death, and almost 40% of these hospitalizations required
blood transfusions. This significant rate of infection is
consistent with previous data that has demonstrated in-
fection as a major driver of early MM death [5]. Al-
though our dataset cannot differentiate early vs. late
MM mortality, our data demonstrates that infection
plays an important role throughout its disease course [6,
14]. Although prophylactic antibiotics are now increas-
ingly used in induction [15], their value and use later in
the disease course is worthy of further attention.
The high requirement for transfusions for MM pa-
tients seen at the end of life likely led to a delay in
utilization of hospice services. It is not possible to infer
the exact reason for hospitalization using the National
Inpatient Sample but given the high burden of transfu-
sions in our dataset, it is reasonable to infer that a sig-
nificant proportion of hospitalizations were due to
transfusion requirements. Lack of access to transfusions
is a well-recognized barrier to enrollment on hospice.
Hospice agencies often do not have the financial re-
sources to provide these transfusions because most
payers, such as Medicare, reimburse at a fixed daily rate
for patients, irrespective of service types provided [16,
17]. However, allowing transfusions during hospice may
be more cost effective for overall health system as it may
increase hospice enrollment, which has been associated
with lower rates of inpatient death, ICU admission in
the last 30 days of life, and chemotherapy use in the last
two weeks of life [17–21].
We also found charges increased significantly during
our time period, doubling even when adjusted for infla-
tion. Allowing for earlier access to transfusions and
Fig. 2 Trends of Deaths and Palliative Consults for MM Hospitalized Patients
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palliative care/hospice can prevent many of these admis-
sions, and lead to less health-care resource utilization
for patients with MM. Earlier work using Medicare data
has shown that hospice usage has been increasing for
patients with MM, increasing from 28.5% in 2000 to
56.5% by 2013, with only a slight decrease in aggressive
end-of-life care (59.2% in 2000 to 56.7% in 2013, 21].
This information taken together with our data highlights
the significant burden of patients with MM dying in the
hospital and identifies the need for dramatic improve-
ment in this area.
There are several important limitations to our study. It
did not include information on outpatient encounters or
stays in rehabilitation centers or acute care hospitals,
and thus palliative care/hospice usage as an outpatient
cannot be ascertained from our dataset. In addition, it
did not include clinical data that is specific to cancer
such as performance status, cytogenetic risk, stage of
disease or laboratory data. In addition, our analysis used
aggregate patient data instead of individual patient data
so variable effects on particular patient subgroups could
not be analyzed.
In summation, our study demonstrates a reassuring
decrease in inpatient mortality for patients with MM
over time, although patients continue to die in the hos-
pital at greater rates than the general population. Pallia-
tive care and hospice involvement at the end of life has
increased over time but remains low. Patients with MM
dying in the hospital have a significant requirement for
blood transfusions and have a high infection burden. Fa-
cilitating access to blood transfusions as part of hospice
can increase hospice enrollment and decrease the bur-
den and cost of these hospitalizations. Concerted multi-
disciplinary efforts and further research in this area are
needed in order to further improve our approach to-
wards the end of life in patients with MM.
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